Antipsychotic Drugs Market Report 2026

Antipsychotic Drugs Market Overview

• Antipsychotic Drugs market size has reached to $21.25 billion in 2025 • Expected to grow to $33.26 billion in 2030 at a compound annual growth rate (CAGR) of 9.4% • Growth Driver: Rising Mental Disorders Fuel Growth Of Antipsychotic Drugs Market • Market Trend: Advancements In Subcutaneous Antipsychotic Injections For Enhanced Patient Compliance And Efficacy • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Antipsychotic Drugs Market?

Antipsychotic drugs are a class of medications used primarily to manage and treat symptoms of psychosis, which can include delusions, hallucinations, paranoia, and disordered thinking. Psychosis is commonly associated with psychiatric conditions such as schizophrenia, bipolar disorder, and severe depression. These medications are also sometimes referred to as neuroleptics or major tranquilizers. The main therapeutic class types of antipsychotic drugs are first-generation, second-generation, and third-generation. First-generation drugs were the earliest developed and work mainly by blocking dopamine receptors in the brain, which can help reduce hallucinations and delusions. They are used in various diseases such as schizophrenia, bipolar disorder, unipolar depression, dementia, and others and are sold through several distribution channels, including hospital pharmacies, drug stores, and online pharmacies.

What Is The Antipsychotic Drugs Market Growth Forecast?

The antipsychotic drugs market size is expected to see strong growth in the next few years. It will grow to $33.26 billion in 2030 at a compound annual growth rate (CAGR) of 9.4%. The growth in the forecast period can be attributed to advancements in atypical and partial dopamine agonists, adoption of precision medicine approaches, integration of ai in mental health diagnostics, expansion of online pharmacy distribution, increasing focus on long-acting injectable formulations. Major trends in the forecast period include personalized antipsychotic therapy, rising geriatric population, increasing prevalence of schizophrenia and bipolar disorder, telepsychiatry and digital mental health platforms, development of long-acting injectable antipsychotics.

Global Antipsychotic Drugs Market Segmentation

1) By Therapeutic Class: First Generation, Second Generation, Third Generation 2) By Disease: Schizophrenia, Bipolar Disorder, Unipolar Depression, Dementia, Other Diseases 3) By Distribution Channel: Hospital Pharmacies, Drug Stores, Online Pharmacies Subsegments: 1) By First Generation: Typical Antipsychotics, Phenothiazines, Butyrophenones, Thioxanthenes, Dibenzoxazepines 2) By Second Generation: Atypical Antipsychotics, Clozapine, Olanzapine, Risperidone, Quetiapine, Aripiprazole, Paliperidone, Lurasidone 3) By Third Generation: Partial Dopamine Agonists, Aripiprazole, Brexpiprazole, Cariprazine

What Is The Driver Of The Antipsychotic Drugs Market?

The growing incidence of mental disorders is expected to propel the growth of the antipsychotic drug market going forward. Mental disorders, often known as mental illnesses, are ailments that impact a person's thinking, behavior, mood, and mental health. The mental disorder cases can be affected by stress levels, societal pressures, genetic predisposition, biochemical imbalance, neurodevelopmental issues, and physical health conditions. Antipsychotic drugs control mental disorders by altering the activity of neurotransmitters, primarily dopamine and serotonin, to reduce psychotic symptoms, stabilize mood, and improve cognitive and emotional function. For instance, in November 2023, according to a survey conducted by the Substance Abuse and Mental Health Services Administration (SAMHSA), a US-based government agency for public health, approximately 6% of adults aged 18 or older, equivalent to 15.4 million individuals, reported experiencing serious mental illness (SMI). Furthermore, in September 2024, according to the Australian Institute of Health and Welfare, an Australia-based government agency, the number of individuals living with dementia in Australia is expected to more than double from around 411,100 in 2023 to 849,300 by 2058. This increase will affect approximately 315,500 men and 533,800 women. Therefore, a growing incidence of mental disorders is driving the antipsychotic drug industry.

Key Players In The Global Antipsychotic Drugs Market

Major companies operating in the antipsychotic drugs market are Pfizer Inc., Johnson & Johnson Services Inc., Merck And Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly And Company, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Aurobindo Pharma Ltd., Cipla Ltd., H. Lundbeck A/S, Dr. Reddy’s Laboratories Ltd., Intas Pharmaceuticals Ltd., Apotex Inc., Lupin Limited, Glenmark Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd., Alkermes plc

Global Antipsychotic Drugs Market Trends and Insights

Major companies operating in the antipsychotic drug market are focused on developing advanced medical products, such as subcutaneous atypical antipsychotic injections, to offer improved patient compliance and enhanced efficacy compared to traditional oral medications. Subcutaneous atypical antipsychotic injections are psychiatric drugs that are given under the skin to treat mental illnesses, maintain stable blood levels, and improve symptom control. For instance, in April 2023, Teva Pharmaceutical Industries Ltd., an Israel-based pharmaceutical company, and MedinCell SA, a France-based manufacturer of biological products and pharmaceutical preparations, launched U.S. Food and Drug Administration (FDA)-approved UZEDY. It is an extended-release injectable formulation of risperidone designed as a long-acting subcutaneous injection that offers flexible dosing intervals of one or two months. UZEDY utilizes MedinCell's proprietary SteadyTeq technology, which ensures a steady release of the medication, reaching therapeutic levels within 6–24 hours of administration. In clinical trials, UZEDY demonstrated up to an 80% reduction in the risk of schizophrenia relapse compared to placebo. It is intended to address adherence issues commonly associated with oral antipsychotics, which often lead to relapse.

What Are Latest Mergers And Acquisitions In The Antipsychotic Drugs Market?

In March 2024, Bristol-Myers Squibb, a US-based pharmaceutical company, acquired Karuna Therapeutics Inc. for $14 billion. The acquisition aims to significantly enhance Bristol Myers Squibb's neuroscience portfolio by integrating Karuna's innovative antipsychotic treatment, KarXT. Additionally, the deal provides access to Karuna's early-stage and preclinical pipeline, which may further contribute to the company's long-term growth and diversification in neuroscience. Karuna Therapeutics Inc. is a US-based clinical-stage biopharmaceutical company that develops the treatment of psychiatric and neurological conditions.

Regional Insights

North America was the largest region in the antipsychotic drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Antipsychotic Drugs Market?

The antipsychotic drugs market consists of sales of long-acting injectables, depot injections, and atypical antipsychotics. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Antipsychotic Drugs Market Report 2026?

The antipsychotic drugs market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the antipsychotic drugs industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.